CA-NANOTEMPER
NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who now have the ability to optimize purification schemes for challenging, low-yield targets much faster, and with unprecedented insights on thermal stability during expression screening.
“At NanoTemper, our vision of creating a world where every disease is treatable starts here, in early drug development. Without high-quality drug targets or protein therapeutics, researchers cannot realize this vision. So, we’ve adapted our reliable and trusted optics systems to provide valuable insights for those working to express and purify these critical targets,” says Dr. Philipp Baaske, co-CEO of NanoTemper.
Dr. Amit Gupta, Head of Product Management at NanoTemper, adds, “Andromeda X incorporates our Spectral Shift optics, which are precision engineered to be sensitive enough to reveal expression levels and stability characterization from small batch crude lysates before teams commit to a purification scheme. Andromeda X gives expression insights in less time than traditional SDS-PAGE gels and provides additional information on the foldedness and functionality of the recombinant proteins.”
With Andromeda X, protein production teams can now hand over high-quality recombinant proteins faster and save themselves the trouble of re-screening or chasing unpromising leads by assessing the stability of proteins early on. Andromeda provides all of the valuable information needed to help them quickly and efficiently select for conditions that result in expression of quality proteins.
Visit nanotempertech.com/andromeda to find out more details.
About NanoTemper Technologies
At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable biophysical tools that bring them the clarity, confidence, and momentum they need to discover and develop future therapies, even difficult ones. Because the path to a disease-free world requires courage, big thinking, and collaboration, we’ll continue to create innovative products that meet the needs of our customers as they face new and difficult challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503533952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Princess Alexandra Hospital NHS Trust Enhances its Cybersecurity with Armis19.2.2025 09:00:00 CET | Press release
Healthcare delivery organization effectively balances innovation and security to drive improved quality of care Armis, the cyber exposure management & security company, today announced that it is enabling The Princess Alexandra Hospital NHS Trust (PAHT) to protect its entire attack surface and manage cyber risk exposure in real time, underpinning the delivery of world-class patient care. PAHT leverages AI-powered Armis CentrixTM, the Armis Cyber Exposure Management Platform, to proactively identify and mitigate all cyber asset risks, remediate security findings and vulnerabilities and protect the entire attack surface. Armis CentrixTM for Medical Device Security is a specialized solution engineered to protect healthcare institutions from the growing threat landscape targeting medical devices. “Putting quality first is the Trust’s approach to everything we do as we strive for excellence, and cybersecurity is no exception,” said Jeffrey Wood, Deputy Director of ICT at PAHT. “Armis has su
SES Enables Viasat Energy Services’ Asia-Pacific Customer to Experience High-Performance Connectivity19.2.2025 08:50:00 CET | Press release
SES’s O3b mPOWER enhances offshore operations with high-performance connectivity to a Floating Production Storage and Offloading (FPSO) vessel SES announced today that O3b mPOWER, its second-generation medium Earth orbit (MEO) satellite system, was deployed to a Viasat Energy Services’ customer operating an offshore vessel in the Asia-Pacific (APAC) region. This collaboration represents Viasat Energy’s first adoption of MEO satellite technology in APAC and their inaugural implementation of O3b mPOWER services globally. Offshore Energy mPOWERED was deployed in late October 2024 aboard a Floating Production Storage and Offloading Vessel (FPSO), delivering high-performance connectivity tailored to the specific needs of the offshore energy sector. The O3b mPOWER connectivity will support both critical and non-critical communications onboard, ensuring reliable, high-speed connectivity with guaranteed service level agreement (SLA). This deployment marks a significant step forward in enabling
Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)19.2.2025 07:00:00 CET | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications. Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications. In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution. "As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Pe
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars19.2.2025 03:57:00 CET | Press release
Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab) in the EU marketEuropean Commission approval based on totality of evidence including extensive comparative analytical, pharmacokinetic and clinical dataThe company expands its biosimilar portfolio to 11 in 2025 as planned, further strengthening its commitment to a portfolio of 22 drugs by 2030 Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic CNV); and Stoboclo® and Osenvelt® (CT-P41, denosumab), biosimilars ref
IFF Reports Fourth Quarter and Full Year 2024 Results18.2.2025 22:49:00 CET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Management Commentary "IFF delivered a solid performance in 2024, reflecting the hard work and dedication of our global team,” said CEO Erik Fyrwald. "Their commitment to serving our customers with industry-leading innovation drove strong top and bottom-line financial results. I’m pleased with the significant progress we’ve made over the past year yet believe that we still have more work to do to realize IFF's full potential. In 2025, we'll strategically increase our investment in R&D, commercial, capacity and technology as we aim to continue to strengthen IFF. Recognizing ongoing macroeconomic uncertainties, we remain confident in our strategy and our ability to navigate challenges as we continue to create long-term value for all shareholders." Full year 2024 Consolidated Financial Results Reported net sales for the full year were $11.48 billion,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom